

# Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y<sub>1</sub> and the P2Y<sub>12</sub> receptor and is correlated with protein expression of P2Y<sub>12</sub>

Oscar Ö Braun · Stefan Amisten ·  
Anna-Karin Wihlborg · Karen Hunting ·  
David Nilsson · David Erlinge

Received: 18 May 2006 / Accepted: 27 September 2006 / Published online: 30 November 2006  
© Springer Science + Business Media B.V. 2006

**Abstract** Two ADP receptors have been identified on human platelets: P2Y<sub>1</sub> and P2Y<sub>12</sub>. The P2Y<sub>12</sub> receptor blocker clopidogrel is widely used to reduce the risks in acute coronary syndromes, but, currently, there is no P2Y<sub>1</sub> blocker in clinical use. Evidence for variable responses to clopidogrel has been described in several reports. The mechanistic explanation for this phenomenon is not fully understood. The aim of this study was to examine mechanisms responsible for variability of 2MeS-ADP, a stable ADP analogue, induced platelet reactivity in clopidogrel-treated patients. Platelet reactivity was assessed by flow cytometry measurements of P-selectin (CD62P) and activated GpIIb/IIIa complex (PAC-1). Residual 2MeS-ADP activation via the P2Y<sub>12</sub> and P2Y<sub>1</sub> receptors was determined by co-incubation with the selective antagonists AR-C69931 and MRS2179 in vitro. P2Y<sub>1</sub> and P2Y<sub>12</sub> receptor expression on both RNA and protein level were determined, as well as the P2Y<sub>12</sub> H1 or H2 haplotypes. Our data suggest that the residual platelet activation of 2MeS-ADP after clopidogrel treatment is partly due to an inadequate antagonistic effect of clopidogrel on the P2Y<sub>12</sub> receptor and partly due to activation of the P2Y<sub>1</sub> receptor, which is unaffected by clopidogrel. Moreover, a correlation between increased P2Y<sub>12</sub> protein expression on platelets and decreased response to clopidogrel was noticed,  $r^2=0.43$  ( $P<0.05$ ). No correlation was found between P2Y<sub>12</sub> mRNA

levels and clopidogrel resistance, indicating post-transcriptional mechanisms. To achieve additional ADP inhibition in platelets, antagonists directed at the P2Y<sub>1</sub> receptor could be more promising than the development of more potent P2Y<sub>12</sub> receptor antagonists.

**Key words** AR-C 69931 · clopidogrel · MRS 2179 · P2Y<sub>1</sub> · P2Y<sub>12</sub> · platelets

## Introduction

ADP receptors play an important role in the activation of platelets by acting as a positive feedback mechanism. There is evidence of two different ADP receptors expressed on human platelets: the Gq-coupled P2Y<sub>1</sub> and the Gi-coupled P2Y<sub>12</sub> [1, 2]. The P2Y<sub>12</sub> antagonist clopidogrel has been shown to be an important platelet inhibitor. The Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) and Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) studies demonstrate that inhibition of the P2Y<sub>12</sub> receptor is beneficial, both alone and as a complement to standard aspirin treatment [3, 4]. At present, the standard regimen after a non-ST elevation myocardial infarction or coronary stenting is a combined treatment with both clopidogrel and aspirin.

However, evidence for a variable response to clopidogrel has recently been studied [5–7], and clopidogrel resistance has been associated with an increase in cardiovascular events [8]. The mechanisms underlying this phenomenon have not been fully elucidated. An association of clopidogrel resistance with the activity of the hepatic cytochrome

O. Ö. Braun · S. Amisten · A.-K. Wihlborg · K. Hunting ·  
D. Nilsson · D. Erlinge (✉)  
Department of Cardiology, Lund University Hospital,  
221 85 Lund, Sweden  
e-mail: david.erlinge@med.lu.se

CYP3A4 has been suggested [9]. Medication with atorvastatin has also been proposed to influence the metabolism of clopidogrel, by acting as a competitive substrate for CYP3A4 [10]. However, later studies have not been able to confirm this relationship [11–13]. Other potential explanations may be variations in receptor expression and function or variation in intracellular signaling pathways. A single nucleotide polymorphism (SNP) in the P2Y<sub>12</sub> receptor associated with increased function of the receptor and increased risk for peripheral arterial disease (PAD) has been described and characterized [14, 15]. Again, a more recent study has not been able to confirm this association [16]. It is also plausible that the second ADP receptor expressed on human platelets, P2Y<sub>1</sub>, may be involved in the insufficient inhibition of ADP-mediated platelet activation after clopidogrel treatment.

We recently developed a real-time quantitative polymerase chain reaction (PCR) method for studies of transcriptional regulation of specific mRNA transcript in human platelets [1]. It has been useful in clinical studies demonstrating a down-regulation of P2Y<sub>12</sub> receptor mRNA in patients with systemic lupus erythematosus (SLE) compared with healthy controls [17].

The aim of the present study was to investigate whether residual 2MeS-ADP, a stable ADP analogue, induced platelet reactivity after clopidogrel treatment due to unblocked P2Y<sub>1</sub> or to insufficient inhibition of P2Y<sub>12</sub> receptor activity. We were also interested in evaluating if variations in residual platelet reactivity after clopidogrel treatment could be correlated with receptor properties: P2Y<sub>12</sub> expression, on mRNA or protein level, or to the P2Y<sub>12</sub> haplotype.

## Material and methods

### Selection of patients

Our study group consisted of 19 patients (six women and 13 men) recently treated by percutaneous coronary intervention (PCI). Blood samples were collected during a visit to an out patient clinic, at least 2 weeks after the intervention. All patients were on both aspirin and clopidogrel and had a median age of 66 years (range 49–84 years). Eight had a history of previous acute myocardial infarction, and four had documented diabetes mellitus. There were 17 on statins and 14 on either angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers.

The Ethics Committee of Lund University approved the project. All patients had given written consent prior to participation in the study.

### Blood collection and handling

For flow cytometry, blood was collected in vacutainer 4.5 ml citrate tubes. All experimental procedures were carried out as fast as possible and always within 10 min of blood collection. For RNA and protein analysis, blood was drawn in six vacuette 6 ml EDTA tubes. Platelet rich plasma (PRP) was then prepared by centrifugation at 160 *g* for 20 min at 4°C. PRP was carefully collected without disturbance of the buffy coat and was centrifuged again at 160 *g* for 10 min at 4°C to remove contaminating leukocytes. The PRP was then transferred to a new tube, and the platelets were collected by centrifugation at 1000 *g* for 10 min at 4°C. The platelet pellet was immediately dissolved in 1 ml TRIzol and frozen at –80°C.

### Flow cytometric assessment of platelet activation

Flow cytometric studies were performed on a Becton and Dickinson FacScan. The following antibodies were used: fluorescein isothiocyanate (FITC)-conjugated anti-GPIIb/IIIa (PAC-1) antibody, phycoerythrin (PE)-conjugated anti-P-selectin (CD62P) and peridinin chlorophyll-a protein (PerCP)-conjugated anti-CD61. 2MeS-ADP (1 μM) was used as a stable P2Y agonist. We used the same concentration, 10 μM, of both antagonists, AR-C 69931 and MRS 2179, based on a dose-finding study made prior to the clinical study. AR-C 69931 is more potent (IC<sub>50</sub> around 0.4 nM) than MRS 2179 (reported IC<sub>50</sub> in human platelets 147 nM), but the fact that the P2Y<sub>12</sub> receptor in the clopidogrel-treated patient is already partly blocked changes this relationship [18, 19]. To achieve roughly the same amount of inhibition a more potent P2Y<sub>12</sub> antagonist is needed. Five microliters of whole blood was incubated in phosphate buffered saline (PBS) solution, pH 7.4, containing agonist, appropriate antagonist and saturating concentrations of antibodies in a total volume of 50 μl for 20 min in the dark at room temperature. The reaction was then stopped by the addition of 3 ml 1% paraformaldehyde solution at 4°C followed by 20 min incubation at 4°C in the dark. Three-color flow cytometry was then performed. Forward scatter and side scatter were used to gate the platelet population. A total of 10,000 gated events was collected. To further exclude other cell types, we included only CD61 positive cells in the analysis. P-selectin positive platelets were quantified by determining the percentage of cells with fluorescence greater than mouse IgG control. For anti-GPIIb/IIIa antibody, PAC-1, the mean fluorescence intensities (MFIs) were measured. Inhibition of platelet activation was expressed as the relative inhibition of platelet activation after addition of drugs compared with stimulated platelets.

## RNA and protein extraction

Total cellular RNA and protein was extracted using TRIzol reagent (Gibco BRL, Life Technology) according to the supplier's instructions. The RNA concentration was determined spectrophotometrically, with a ratio of optical density (OD)<sub>260:280</sub> > 1.6 being considered as pure. Samples were stored at  $-70^{\circ}\text{C}$  until required. The quality of RNA and protein was fully satisfactory in only 14 subjects. Protein pellets were vacuum dried and dissolved in 1% sodium dodecyl sulfate solution. DC protein assay (BioRad Laboratories, USA) was used to determine protein concentrations. Protein samples were stored at  $-20^{\circ}\text{C}$  until required.

## Quantitative analysis of P2 receptors by real-time reverse transcription polymerase chain reaction

Total RNA was reverse-transcribed using Multiscribe RT Kit (Qiagen, CA, USA) following the manufacturer's instructions. Real-time PCR on platelet cDNA was performed using the following primers: P2Y<sub>12</sub> 5'-CTATCGATCGCTACCA GAAGAC-3', 5'-TCATGCCAGACTAGACCGAA-3', GAPDH 5'-GTCCACTGGCGTCTTCACCA-3', 5'-GTGGCAGTGATGGCATGGAC-3'. Relative gene expression levels were determined using LightCycler (Roche, Basle, Switzerland). As a template, 1  $\mu\text{l}$  platelet cDNA was used in a total volume of 10  $\mu\text{l}$  [3 mM MgCl<sub>2</sub>, 0.5  $\mu\text{M}$  of each primer (described below) and 1 $\times$ LightCycler DNA Master SYBR Green I mix (Roche)]. The following PCR amplification protocol was used: initial denaturation at  $95^{\circ}\text{C}$  for 600 s, followed by 45 PCR cycles at  $95^{\circ}\text{C}$  for 1 s,  $55^{\circ}\text{C}$  (P2Y<sub>12</sub>) or  $58^{\circ}\text{C}$  (GAPDH) respectively for 6 s, and  $74^{\circ}\text{C}$  for 23 s. Target gene amplification levels were quantified using a second-derivative maximum method available in the LightCycler software. P2Y<sub>12</sub> receptor expression was determined using the housekeeping gene GAPDH as a reference. To validate specificity of amplification reactions, the LightCycler PCR products were sequenced using BigDye v.3.1 (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions.

## Sodium dodecyl sulfate–polyacrylamide gel electrophoresis and western blotting

Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting were performed as described elsewhere [20]. Briefly, 20  $\mu\text{g}$  protein per lane was separated using 10% SDS-polyacrylamide gels and transferred onto Immobilon-P membranes (Millipore, Bedford, MA, USA). Sequential detection of P2Y<sub>1</sub> and P2Y<sub>12</sub> (at 1:200 dilution) and GAPDH (at 1:500 dilution) was

performed according to the following procedure in the above-mentioned order. Membranes were incubated for 1 h at room temperature with the appropriate primary antibody, washed three times with TBS 0.1% Tween, incubated for 1 h with HRP-conjugated secondary antibodies, washed three times and visualized using the ECL western blotting system and Hyperfilm. After each round of immunodetection, the membranes were incubated for 30 min at  $50^{\circ}\text{C}$  in stripping buffer (100 mM 2-mercapto-ethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.7) to remove previously bound antibodies, washed twice in TBS 0.1 % Tween, blocked with 5% fat-free milk in TBS 0.1% Tween and used again for the next set of antibodies.

The signal intensity (integral volume) of the appropriately sized bands was scanned and analyzed using Quantity One software (BioRad). The signal intensities of the different P2 receptors were normalized to GAPDH to account for variations in the amounts of total protein present in each lane.

## Determination of P2Y<sub>12</sub> haplotype

DNA was isolated from whole blood using the TRIzol reagent according to the manufacturer's instructions. A PCR using HotStarTaq (Qiagen) and the primers 5'-GAGCACTCAAGACTTTACTGACG-3' and 5'-GAGAA GATCAGAAATGACTGTGTTC-3' was used to amplify the entire second and parts of the third exon of the of the P2Y<sub>12</sub> gene. The 2233 bp amplification product, containing two *Tai*I restriction sites, [at polymorphism i-T744C (1008 bp from the 5' end of the amplification product)] and at a control *Tai*I site (at 1588 bp), was diluted three times with water, digested for 1 h with 2U *Tai*I at  $65^{\circ}\text{C}$  in a total volume of 30  $\mu\text{l}$  and visualized by agarose gel electrophoresis. The P2Y<sub>12</sub> H1 allele was identified by the presence of two bands (1588 bp- and 645 bp-long restriction fragments), and the H2 allele by three bands (1008 bp-, 580 bp- and 465 bp-long restriction fragments) [13].

## Reagents, antibodies and drugs

Unless otherwise stated all reagents and drugs were purchased from Sigma Chemical Corp., St. Louis, MI, USA. PCR and RT-PCR consumables were purchased from Perkin-Elmer Applied Biosystems Inc., Foster City, CA, USA. PCR primers were from MWG Biotech AG, Ebersberg, Germany and TRIzol from Invitrogen, Carlsbad, CA, USA. Western blot reagents were from Amersham Pharmacia Biotech, UK, or Bio-Rad Laboratories, USA. Anti-P2Y<sub>1</sub> and anti- P2Y<sub>12</sub> antibodies were purchased from Alomone Labs, Israel, and the anti-GAPDH was from Chemicon, USA. Anti-CD61, anti-CD62P and anti-PAC1 antibodies

were from BD, USA. MRS 2179 was from Tocris, and AR-C 69931 was a kind gift from Astra-Zeneca, Sweden. All drugs were dissolved in 0.9% saline solution.

### Statistics and analysis

Calculations and statistics were performed using GraphPad Prism 4.00 software. Repeated-measures analysis of variance (ANOVA) with Bonferroni's post-test was used to compare flow cytometry data. Values are presented as mean  $\pm$  SEM. Comparison of quantitative real-time data was performed using the method described by Pfaffl [21]. The amplification efficiencies of each primer pair were tested prior to analysis.

## Results

### Flow cytometry assessment of platelet activation


After stimulation of platelets with 1  $\mu$ M 2MeS-ADP, additional antagonism of the P2Y<sub>12</sub> receptor with AR-C 69931 (10  $\mu$ M), to platelets from patients already treated with

clopidogrel and aspirin, inhibited the residual percentage of P-selectin positive platelets by 35.8 $\pm$ 3.5% (mean  $\pm$  SEM) ( $n$ =19) and the expression of activated GPIIb/IIIa by 43.5 $\pm$ 3.4%. The blocking of the P2Y<sub>1</sub> receptor with MRS 2179 (10  $\mu$ M) resulted in a significantly greater inhibition of the percentage of P-selectin positive platelets by 67.3 $\pm$ 4.4% and of activated GPIIb/IIIa to 54.2 $\pm$ 2.6%. Combining the antagonists yielded an even greater significant inhibition: 78.4 $\pm$ 3.8% for P-selectin and 72.2 $\pm$ 2.5% for GPIIb/IIIa. Data are presented in Figure 1.


### Correlation of function with protein and RNA expression

Proteins were run on western blot, and bands from the P2Y<sub>12</sub> receptor and GAPDH were detected. Signal intensities were quantified, and each P2Y<sub>12</sub> reading was normalized to the GAPDH expression in the same sample to correlate with different loading amounts. The relative normalized expression of P2Y<sub>12</sub> protein correlated with the percentage of cells expressing P-selectin after stimulation by 2MeS-ADP, with a linear regression of  $r^2=0.43$  ( $P<0.05$ ) ( $n$ =14). No correlations were found between P2Y<sub>1</sub> protein levels and P-selectin positive platelets ( $r^2=0.002$ ,  $P=0.88$ ,  $n$ =14). Data are presented in Figure 2.

### a Inhibition of P-selectin positive platelets




### b Inhibition of activated GPIIb/IIIa



**Figure 1** Graph showing the increased inhibition of residual ADP-induced P-selectin positive platelets (**a**) and expression of activated GPIIb/IIIa (**b**) after the further blocking of the P2Y<sub>12</sub> receptor with AR-C 69931 (10  $\mu$ M) and the P2Y<sub>1</sub> receptor with MRS 2179 (10  $\mu$ M) and the blocking of both receptors with a combination of both antagonists. These effects are seen in platelets already blocked by clopidogrel and aspirin. Blocking the P2Y<sub>12</sub> receptor further with AR-C 69931 (10  $\mu$ M) significantly inhibited the percentage of P-selectin positive platelets by 35.8 $\pm$ 3.5% (mean  $\pm$  SEM) ( $n$ =19) and the expression of activated GPIIb/

IIIa by 43.5 $\pm$ 3.4%. A significantly greater inhibition was seen when the P2Y<sub>1</sub> antagonist MRS 2179 (10  $\mu$ M) was used, where the inhibition of P-selectin increased to 67.3 $\pm$ 4.4% and the inhibition of activated GPIIb/IIIa increased to 54.2 $\pm$ 2.6%. Combining the antagonists yielded an even greater significant inhibition: 78.4 $\pm$ 3.8% for P-selectin and 72.2 $\pm$ 2.5% for activated GPIIb/IIIa. There were significance differences between the groups,  $P<0.01$ , in all cases ( $n$ =19). Repeated-measures ANOVA with Bonferroni's post-test were used to compare data



**Figure 2** The relative expression and GAPDH-normalized expression of P2Y<sub>12</sub> (a) and P2Y<sub>1</sub> (b) protein correlated with the percentage of P-selectin positive platelets after stimulation with 1  $\mu$ M of 2MeS-ADP. In (a) there is a significant correlation of P-selectin positive platelets

with P2Y<sub>12</sub> protein expression, with  $r^2=0.43$  ( $P<0.05$ ) ( $n=14$ ). In (b) there is no significant correlation of P-selectin positive platelets and P2Y<sub>1</sub> protein expression ( $r^2=0.002$ ,  $P=0.88$ ,  $n=14$ ) (*pos plts* positive platelets)

P2Y<sub>12</sub> and GAPDH mRNA expressions were quantified, and no correlation was found between the relative expression levels of the P2Y<sub>12</sub> mRNA and the percentage of cells expressing P-selectin or activated GPIIb/IIIa after stimulation with 2MeS-ADP ( $r^2=0.30$ ,  $P=0.20$  for P-selectin;  $r^2=0.04$ ,  $P=0.19$  for GPIIb/IIIa) (data not shown).

#### P2Y<sub>12</sub> haplotype and function

The haplotype was determined by PCR sequencing and restriction digestion. Thirteen patients were homozygous for the H1 haplotype (H1/H1) and six patients were heterozygous (H1/H2), whereas none of the patients was homozygous for the H2 haplotype. There was no difference in the percentage of platelets expressing P-selectin after 2MeS-ADP (1  $\mu$ M) in the homozygous (H1/H1) group compared with the heterozygous (H1/H2) group ( $45.2\pm6.4\%$  for H1/H1 vs  $37.0\pm9.0\%$  for H1/H2,  $P=0.47$ ) (unpaired *t*-test).

#### Discussion

This study suggests that the residual 2MeS-ADP platelet reactivity after clopidogrel treatment is in part due to an inadequate antagonistic effect of clopidogrel on the P2Y<sub>12</sub> receptor and partly due to the P2Y<sub>1</sub> receptor, which is unaffected by clopidogrel. Moreover, a correlation between increased P2Y<sub>12</sub> protein expression on platelets and decreased response to clopidogrel was noticed. No correlation was seen between platelet activation and P2Y<sub>12</sub> mRNA expression or the P2Y<sub>12</sub> H1/H2 haplotype.

Our cohort of patients was chosen to reflect the real clinical situation as much as possible, resulting in a heterogeneous group having other illnesses and taking several other medications apart from clopidogrel and aspirin. The *cohort* was too small for us to be able to do any

subgroup analyses in terms of other medication, previous diseases or gender. Since all of the patients were on aspirin, the impact of reduced prostaglandin synthesis was *present throughout*. Despite the inhibition by both clopidogrel and aspirin, we were able to activate their platelets further with 2MeS-ADP. The remaining 2MeS-ADP activation was dependent on both insufficient P2Y<sub>12</sub> blockade by clopidogrel and the unaffected ADP receptor P2Y<sub>1</sub>. Most likely, many different factors contribute to produce the observed clinical phenotype. One of the most important factors is still the second ADP receptor, P2Y<sub>1</sub>, that remains totally unaffected by clopidogrel. To achieve full ADP inhibition in the future, increasing the effect of clopidogrel or other P2Y<sub>12</sub> blockers will not suffice. Thus, the clinical benefit of a P2Y<sub>1</sub> blocker will be an interesting alternative.

Despite the use of both AR-C 6931 and MRS 2179, platelets were not completely inhibited after 2MeS-ADP stimulation. This was probably due to the very high concentration of agonist used to stimulate the system; 1  $\mu$ M of 2MeS-ADP corresponds to a significantly higher dose of unmodified ADP. The platelet stimulation was also conducted in whole blood, where leukocytes and erythrocytes may also influence the degree of platelet stimulation.

Resistance to the COX-1 inhibitor acetylsalicylic acid (aspirin) has been studied and debated for many years. Small observational studies suggest that non-responders to aspirin are at greater risk of cardiovascular events than are responders [22–25]. Recently, resistance to clopidogrel has emerged as an interesting occurrence with a clear clinical relevance [6–8]. The fact that clopidogrel resistance has an impact on the cardiovascular outcome in patients with coronary artery disease merits further studies to elucidate the underlying mechanisms [8]. Theoretically, many factors may influence the clopidogrel response: bioavailability, genetic or transcriptional variations in the metabolizing enzymes or in the target receptor and interactions with other



compounds. One early study demonstrated a correlation between clopidogrel resistance and atorvastatin medication, but this hypothesis was later dismissed by several other studies [11–13]. Currently, two studies have investigated possible mechanisms underlying clopidogrel resistance. One study was focused on the hepatic metabolism of the drug, and the other was focused on the bioavailability of clopidogrel [9, 26]. The bioavailability and the hepatic metabolism of the pro-drug clopidogrel do seem to be important for clopidogrel resistance [9, 26]. For the first time we find that increased platelet P2Y<sub>12</sub> receptor protein expression is a component of clopidogrel resistance. Increased abundance of a receptor protein may thereby result in less inhibition by its antagonist. However, whether these patients are constituent high P2Y<sub>12</sub> expressers that increase their risk of myocardial infarction is not known. Animal studies have shown a correlation between function and overexpression of P2Y<sub>1</sub> protein, but we could not find this association in our clinical material [27].

Platelets are anuclear cells and are therefore unable to produce new nuclear-derived mRNA transcripts. However, it has been shown that platelets contain megakaryocyte-derived mRNA that can be activated upon platelet stimulation to produce, for example, IL1- $\beta$  and PAI-1 [28, 29]. Thus, translational regulation can account for the variation in protein expression. Interestingly, there was no correlation between P2Y<sub>12</sub> mRNA levels and variation of clopidogrel inhibition. These results suggest that post-transcriptional regulation of the P2Y<sub>12</sub> receptor expression is responsible for the correlation between P2Y<sub>12</sub> protein expression and the clopidogrel effect. Also, mRNA concentrations in platelets are low, and any mRNA correlation that might have existed in the megakaryocyte may have been lost in circulating platelets.

Haplotype studies have suggested that the P2Y<sub>12</sub> H2 haplotype may have a higher mRNA expression than the H1 haplotype, and that this would explain the functional differences between the different genotypes [14]. In our small sample group we could not find any such correlation, and our results are in concordance with a larger P2Y<sub>12</sub> haplotype study by Hetherington et al. [16]. It should be emphasized that our sample is small and it is therefore hard to draw any reliable conclusions between polymorphisms and function.

There are several P2Y<sub>12</sub> antagonistic compounds in early and late clinical trials at the moment: prasugrel, cangrelor, AZD6140. It will be very interesting to see if these will encounter the same response variation problems as clopidogrel has. It might also be that different drugs will be better suited for different clinical phenotypes. With many different P2Y<sub>12</sub> antagonists available in the clinic, a simple clinical test evaluating patient phenotype would be useful in choosing the optimal platelet inhibitor. This study also

shows the relevance of designing drugs targeting the P2Y<sub>1</sub> receptor.

## Conclusion

Variation of clopidogrel inhibition is partly due to the unblocked P2Y<sub>1</sub> receptor and partly due to a variable antagonistic effect of clopidogrel on the P2Y<sub>12</sub> receptor. A correlation between increased P2Y<sub>12</sub> protein expression on platelets and decreased response to clopidogrel was seen, indicating a novel explanation to the clopidogrel resistance phenomenon.

**Acknowledgments** A special thanks to Goran Olivecrona for helpful linguistic guidance. The study was supported by the Swedish Heart and Lung Foundation, the Franke and Margareta Bergqvist Foundation, the Bergwall Foundation, the Zoegas Foundation and Swedish Medical Research Council Grant 13130.

## References

1. Wang L, Ostberg O, Wihlborg A-K, Brogren H, Jern S, Erlinge D (2003) Quantification of ADP and ATP receptor expression in human platelets. *J Thromb Haemost* 1:328–334
2. Kunapuli SP, Dorsam RT, Kim S, Quinton TM (2003) Platelet purinergic receptors. *Curr Opin Pharmacol* 3:175–180
3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 345:494–502
4. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet* 348:1329–1339
5. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. *Circulation* 107:2908–2913
6. Jaremo P, Lindahl TL, Fransson SG, Richter A (2002) Individual variations of platelet inhibition after loading doses of clopidogrel. *J Intern Med* 252:233–238
7. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M (2003) Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. *Thromb Haemost* 89:783–787
8. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. *Circulation* 109:3171–3175
9. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, et al (2004) Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. *Circulation* 109:166–171
10. Lau WC, Waskell LA, Watkins PB, Neer CJ, Hopp AS, et al (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction. *Circulation* 107:32–37
11. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, et al (2003) Lack of adverse clopidogrel–atorvastatin

- clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. *Circulation* 108:921–924
12. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD (2004) Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. *Circulation* 109:1335–1338
  13. Wienbergen H, Gitt AK, Schiele R, Juenger C, Heer T, Meisenzahl C, et al (2003) Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. *Am J Cardiol* 92:285–288
  14. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, et al (2003) Adenosine diphosphate-induced platelet aggregation is associated with P2Y<sub>12</sub> gene sequence variations in healthy subjects. *Circulation* 108:989–995
  15. Fontana P, Gaussem P, Aiach M, Fiessinger JN, Emmerich J, Reny JL (2003) P2Y<sub>12</sub> H2 haplotype is associated with peripheral arterial disease: a case–control study. *Circulation* 108:2971–2973
  16. Hetherington SL, Singh RK, Lodwick D, Thompson JR, Goodall AH, Samani NJ (2005) Dimorphism in the P2Y<sub>1</sub> ADP receptor gene is associated with increased platelet activation response to ADP. *Arterioscler Thromb Vasc Biol* 25:252–257
  17. Wang L, Erling P, Bengtsson AA, Truedsson L, Sturfelt G, Erlinge D (2004) Transcriptional down-regulation of the platelet ADP receptor P2Y<sub>12</sub> and clusterin in patients with systemic lupus erythematosus. *J Thromb Haemost* 2:1436–1442
  18. Burnstock G, Williams M (2000) P2 purinergic receptors: modulation of cell function and therapeutic potential. *J Pharmacol Exp Ther* 295:862–869
  19. Pillarisetti K, Toomey J, Erhardt J (2003) ADP mediated platelet–leukocyte interactions require activation of both P2Y<sub>1</sub> and P2Y<sub>12</sub> receptors. In: Carrico C (ed) Mid-Atlantic Pharmacology Society meeting, 2003. The American Society for Pharmacology and Experimental Therapeutics, 2003; p 139
  20. Wang L, Karlsson L, Moses S, Hultgardh-Nilsson A, Andersson M, Borna C, et al (2002) P2 receptor expression profiles in human vascular smooth muscle and endothelial cells. *J Cardiovasc Pharmacol* 40:841–853
  21. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res* 29:e45
  22. Chen WH, Lee PY, Ng W, Tse HF, Lau CP (2004) Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. *J Am Coll Cardiol* 43:1122–1126
  23. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, et al (1997) Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. *Thromb Haemost* 78:1003–1007
  24. Grotmeyer KH, Scharafinski HW, Husstedt IW (1993) Two-year follow-up of aspirin responder and aspirin non-responder. A pilot-study including 180 post-stroke patients. *Thromb Res* 71:397–403
  25. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. *J Am Coll Cardiol* 41:961–965
  26. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, et al (2004) Pharmacokinetics of clopidogrel after administration of a high loading dose. *Thromb Haemost* 92:311–316
  27. Hechler B, Zhang Y, Eckly A, Cazenave JP, Gachet C, Ravid K (2003) Lineage-specific overexpression of the P2Y<sub>1</sub> receptor induces platelet hyper-reactivity in transgenic mice. *J Thromb Haemost* 1:155–163
  28. Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S (2004) Platelets synthesize large amounts of active plasminogen activator inhibitor 1. *Blood* 104:3943–3948
  29. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, et al (2001) Activated platelets mediate inflammatory signaling by regulated interleukin 1 $\beta$  synthesis. *J Cell Biol* 154:485–490